The TGF-β, PI3K/Akt and PTEN pathways: Established and proposed biochemical integration in prostate cancer

Biochemical Journal

Volumn 417, Issue 2, 2009, Pages 411-421

  Assinder, Stephen J ^a   Dong, Qihan ^a   Kovacevic, Zaklina ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

N myc downstream regulated gene 1 (NDRG 1); Oncogenesis; Phosphatase and tensin homologue deleted on chromosome 10 (PTEN); Phosphoinositide 3 kinase protein kinase B (PI3K Akt); Transforming growth factor (TGF ); Tumour suppression

Indexed keywords

N-MYC DOWNSTREAM REGULATED GENE-1 (NDRG-1); ONCOGENESIS; PHOSPHATASE AND TENSIN HOMOLOGUE DELETED ON CHROMOSOME 10 (PTEN); PHOSPHOINOSITIDE 3-KINASE/PROTEIN KINASE B (PI3K/AKT); TUMOUR SUPPRESSION;

BIOACTIVITY; CHROMOSOMES; PATIENT TREATMENT; PEPTIDES; STRATEGIC PLANNING;

TUMORS;

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2 ALPHA INHIBITOR; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; ICOSANOID; IRON; IRON CHELATING AGENT; LINOLEIC ACID; LIPOCORTIN 1; LIPOCORTIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SMAD4 PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; IRON DEPLETION; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 58249083478     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20081610     Document Type: Review

References (129)

1. Assinder, S. J. and Nicholson, H. D. (2007) Prostate disease: prostate hyperplasia, prostate cancer, and prostatitis. In Male Reproductive Dysfunction: Pathophysiology and Treatment (Kandeel, F. R., Swerdloff, R. S. and Pryor, J. L., eds), pp. 499-518, Informa Healthcare, New York
2. McDermid, I. (2005) Cancer Incidence Projections, Australia 2002-2011, Australian Institute of Health and Welfare (AIHW), Canberra, Australasian Association of Cancer Registries (AACR), Bruce, Canberra, and the National Cancer Strategies Group (NCSG), Canberra
3. Hussain, A. and Dawson, N. (2000) Management of advanced/metastatic prostate cancer: 2000 update. Oncology (Williston Park, N.Y.) 14, 1677-1688
4. Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P. W., Johansson, J. E., Norlen, B. J. and Holmberg, L. (2002) Quality of life after radical prostatectomy or watchful waiting. N. Engl. J. Med. 347, 790-796
5. Wiebe, E., Rodrigues, G., Lock, M., D'Souza, D. and Stitt, L. (2008) Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml. Can. J. Urol. 15, 4078-4083
6. Frankel, S., Smith, G. D., Donovan, J. and Neal, D. (2003) Screening for prostate cancer. Lancet 361, 1122-1128
7. Massague, J. (1998) TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791
8. Sutkowski, D. M., Fong, C. J., Sensibar, J. A., Rademaker, A. W., Sherwood, E. R., Kozlowski, J. M. and Lee, C. (1992) Interaction of epidermal growth factor and transforming growth factor β in human prostatic epithelial cells in culture. Prostate 21, 133-143
9. Wilding, G. (1991) Response of prostate cancer cells to peptide growth factors: transforming growth factor-β. Cancer Surv. 11, 147-163
10. Guo, Y. and Kyprianou, N. (1998) Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9, 185-193
11. Guo, Y. and Kyprianou, N. (1999) Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 59, 1366-1371
12. Rahimi, R. A. and Leof, E. B. (2007) TGF-β signaling: a tale of two responses. J. Cell Biochem. 102, 593-608
13. Ten Dijke, P., Goumans, M. J., Itoh, F. and Itoh, S. (2002) Regulation of cell proliferation by Smad proteins. J. Cell Physiol. 191, 1-16
14. Sasaki, A., Masuda, Y., Ohta, Y., Ikeda, K. and Watanabe, K. (2001) Filamin associates with Smads and regulates transforming growth factor-β signaling. J. Biol. Chem. 276, 17871-17877
15. Li, Z., Chen, Y., Cao, D., Wang, Y., Chen, G., Zhang, S. and Lu, J. (2006) Glucocorticoid up-regulates transforming growth factor-β (TGF-β) type II receptor and enhances TGF-β signaling in human prostate cancer PC-3 cells. Endocrinology 147, 5259-5267
16. Massague, J., Blain, S. W. and Lo, R. S. (2000) TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309
17. Zhu, M. L., Partin, J. V., Bruckheimer, E. M., Strup, S. E. and Kyprianou, N. (2008) TGF-β signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate 68, 287-295
18. Shariat, S. F., Kattan, M. W., Traxel, E., Andrews, B., Zhu, K., Wheeler, T. M. and Slawin, K. M. (2004) Association of pre- and postoperative plasma levels of transforming growth factor β(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin. Cancer Res. 10, 1992-1999
19. Nelson, E. C., Evans, C. P., Mack, P. C., Devere-White, R. W. and Lara, Jr., P. N. (2007) Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 10, 331-339
20. Tokunaga, E., Oki, E., Egashira, A., Sadanaga, N., Morita, M., Kakeji, Y. and Maehara, Y. (2008) Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Targets 8, 27-36
21. Wright, G. L., Maroulakou, I. G., Eldridge, J., Liby, T. L., Sridharan, V., Tsichlis, P. N. and Muise-Helmericks, R. C. (2008) VEGF stimulation of mitochondrial biogenesis: requirement of Akt3 kinase. FASEB J. 22, 3264-3275
22. Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M., Szabolcs, M., de Jong, R., Oltersdorf, T. et al. (2005) Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol. Cell. Biol. 25, 1869-1878
23. Tschopp, O., Yang, Z. Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J. and Hemmings, B. A. (2005) Essential role of protein kinase B γ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132, 2943-2954
24. Yoeli-Lerner, M. and Toker, A. (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5, 603-605
25. Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W. and Leal, J. F. (2008) The PTEN/PI3K/Akt signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 8, 187-198
26. Cheng, G. Z., Park, S., Shu, S., He, L., Kong, W., Zhang, W., Yuan, Z., Wang, L. H. and Cheng, J. Q. (2008) Advances of Akt pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8, 2-6
27. Gao, N., Zhang, Z., Jiang, B. H. and Shi, X. (2003) Role of PI3K/Akt/ mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310, 1124-1132
28. Wegiel, B., Bjartell, A., Culig, Z. and Persson, J. L. (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int. J. Cancer 122, 1521-1529
29. de la Taille, A., Rubin, M. A., Chen, M. W., Vacherot, F., de Medina, S. G., Burchardt, M., Buttyan, R. and Chopin, D. (2003) β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9, 1801-1807
30. Lee, H. K., Kwak, H. Y., Hur, J., Kim, I. A., Yang, J. S., Park, M. W., Yu, J. and Jeong, S. (2007) β-Catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells. Cancer Res. 67, 9315-9321
31. Yu, Y., Kovacevic, Z. and Richardson, D. R. (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6, 1982-1994
32. Chen, Y., Martinez, L. A., LaCava, M., Coghlan, L. and Conti, C. J. (1998) Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 16, 1913-1920
33. Vignot, S., Faivre, S., Aguirre, D. and Raymond, E. (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16, 525-537
34. Toker, A. (2008) mTOR and Akt signaling in cancer: SGK cycles in. Mol. Cell. 31, 6-8
35. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B. and Hidalgo, M. (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62, 6141-6145
36. Gutierrez-Dalmau, A. and Campistol, J. M. (2007) The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant. 22 (Suppl. 1), 1-16
37. Hengartner, M. O. (2000) The biochemistry of apoptosis. Nature 407, 770-776
38. Cantley, L. C. and Neel, B. G. (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U.S.A. 96, 4240-4245
39. Facher, E. A. and Law, J. C. (1998) PTEN and prostate cancer. J. Med. Genet. 35, 790
40. Sharrard, R. M. and Maitland, N. J. (2000) Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br. J. Cancer 83, 1102-1109
41. Davies, M. A., Koul, D., Dhesi, H., Berman, R., McDonnell, T. J., McConkey, D., Yung, W. K. and Steck, P. A. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 59, 2551-2556
42. Wang, S., Garcia, A. J., Wu, M., Lawson, D. A., Witte, O. N. and Wu, H. (2006) Pten deletion leads to the expansion of a prostatic stem/ progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U.S.A. 103, 1480-1485
43. Bonifant, C. L., Kim, J. S. and Waldman, T. (2007) NHERFs, NEP, MAGUKs, and more: interactions that regulate PTEN. J. Cell. Biochem. 102, 878-885
44. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S. and Mak, T. W. (2001) Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325
45. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947
46. Li, L. and Ross, A. H. (2007) Why is PTEN an important tumor suppressor? J. Cell. Biochem. 102, 1368-1374
47. Sansal, I. and Sellers, W. R. (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963
48. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730
49. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. and Donner, D. B. (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484-5489
50. Chang, C. J., Mulholland, D. J., Valamehr, B., Mosessian, S., Sellers, W. R. and Wu, H. (2008) PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 28, 3281-3289
51. Chang, C. J., Freeman, D. J. and Wu, H. (2004) PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 279, 29841-29848
52. Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P. and Holubar, M. (2000) p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. J. Biol. Chem. 275, 5733-5738
53. Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H. et al. (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141-156
54. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H. and Pollak, M. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566
55. DiGiovanni, J., Kiguchi, K., Frijhoff, A., Wilker, E., Bol, D. K., Beltran, L., Moats, S., Ramirez, A., Jorcano, J. and Conti, C. (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 97, 3455-3460
56. Song, K., Cornelius, S. C., Reiss, M. and Danielpour, D. (2003) Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-β by phosphatidylinositol 3-kinase/ Akt-dependent suppression of the activation of Smad3 but not Smad2. J. Biol. Chem. 278, 38342-38351
57. Mehrian-Shai, R., Chen, C. D., Shi, T., Horvath, S., Nelson, S. F., Reichardt, J. K. and Sawyers, C. L. (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 5563-5568
58. Moore, M. G., Wetterau, L. A., Francis, M. J., Peehl, D. M. and Cohen, P. (2003) Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int. J. Cancer 105, 14-19
59. Kurdistani, S. K., Arizti, P., Reimer, C. L., Sugrue, M. M., Aaronson, S. A. and Lee, S. W. (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 58, 4439-4444
60. Stein, S., Thomas, E. K., Herzog, B., Westfall, M. D., Rocheleau, J. V., Jackson, 2nd, R. S., Wang, M. and Liang, P. (2004) NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 279, 48930-48940
61. Le, N. T. and Richardson, D. R. (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104, 2967-2975
62. Bandyopadhyay, S., Pai, S. K., Gross, S. C., Hirota, S., Hosobe, S., Miura, K., Saito, K., Commes, T., Hayashi, S., Watabe, M. and Watabe, K. (2003) The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 63, 1731-1736
63. Bandyopadhyay, S., Pai, S. K., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., Takano, Y., Saito, K., Commes, T., Piquemal, D. et al. (2004) PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res. 64, 7655-7660
64. Kovacevic, Z., Fu, D. and Richardson, D. R. (2008) The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim. Biophys. Acta 1783, 1981-1992
65. Sluimer, J. C., Gasc, J. M., van Wanroij, J. L., Kisters, N., Groeneweg, M., Sollewijn Gelpke, M. D., Cleutjens, J. P., van den Akker, L. H., Corvol, P., Wouters, B. G. et al. (2008) Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J. Am. Coll. Cardiol. 51, 1258-1265
66. Kovacevic, Z. and Richardson, D. R. (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27, 2355-2366
67. Berger, A. P., Kofler, K., Bektic, J., Rogatsch, H., Steiner, H., Bartsch, G. and Klocker, H. (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 57-65
68. Yoon, G., Kim, H. J., Yoon, Y. S., Cho, H., Lim, I. K. and Lee, J. H. (2002) Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor β1 (TGF-β1)-mediated p27Kip1 expression. Biochem. J. 366, 613-621
69. Fang, J., Ding, M., Yang, L., Liu, L. Z. and Jiang, B. H. (2007) PI3K/ PTEN/Akt signaling regulates prostate tumor angiogenesis. Cell. Signalling 19, 2487-2497
70. Emerling, B. M., Weinberg, F., Liu, J. L., Mak, T. W. and Chandel, N. S. (2008) PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl. Acad. Sci. U.S.A. 105, 2622-2627
71. Wildroudt, M. L. and Freeman, E. J. (2006) Regulation of Akt by arachidonic acid and phosphoinositide 3-kinase in angiotensin II-stimulated vascular smooth muscle cells. Biochim. Biophys. Acta 1761, 11-16
72. 2. Am. J. Physiol. 288, H2306-H2316
73. Li, F. and Malik, K. U. (2005) Angiotensin II-induced Akt activation through the epidermal growth factor receptor in vascular smooth muscle cells is mediated by phospholipid metabolites derived by activation of phospholipase D. J. Pharmacol. Exp. Ther. 312, 1043-1054
74. Gorin, Y., Kim, N. H., Feliers, D., Bhandari, B., Choudhury, G. G. and Abboud, H. E. (2001) Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J. 15, 1909-1920
75. Covey, T. M., Edes, K. and Fitzpatrick, F. A. (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26, 5784-5792
76. Patel, M. I., Kurek, C. and Dong, Q. (2008) The arachidonic acid pathway and its role in prostate cancer development and progression. J. Urol. 179, 1668-1675
77. Hughes-Fulford, M., Li, C. F., Boonyaratanakornkit, J. and Sayyah, S. (2006) Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 66, 1427-1433
78. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M. and Chen, C. S. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275, 11397-11403
79. Patel, M. I., Subbaramaiah, K., Du, B., Chang, M., Yang, P., Newman, R. A., Cordon-Cardo, C., Thaler, H. T. and Dannenberg, A. J. (2005) Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 11, 1999-2007
80. Samuels, Y. and Ericson, K. (2006) Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77-82
81. Gravdal, K., Halvorsen, O. J., Haukaas, S. A. and Akslen, L. A. (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 13, 7003-7011
82. van der Poel, H. G. (2004) Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells. J. Urol. 172, 1333-1337
83. Vogelmann, R., Nguyen-Tat, M. D., Giehl, K., Adler, G., Wedlich, D. and Menke, A. (2005) TGFβ-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3Kinase and PTEN. J. Cell Sci. 118, 4901-4912
84. Button, E., Shapland, C. and Lawson, D. (1995) Actin, its associated proteins and metastasis. Cell Motil. Cytoskeleton 30, 247-251
85. Bakin, A. V., Safina, A., Rinehart, C., Daroqui, C., Darbary, H. and Helfman, D. M. (2004) A critical role of tropomyosins in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol. Biol. Cell 15, 4682-4694
86. Assinder, S. J., Stanton, J. A. and Prasad, P. D. (2008) Transgelin: an actin-binding protein and tumour suppressor. Int. J. Biochem. Cell Biol., doi:10.1016/j.biocel.2008.02.011
87. Guan, R. J., Ford, H. L., Fu, Y., Li, Y., Shaw, L. M. and Pardee, A. B. (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 60, 749-755
88. Kim, K. T., Ongusaha, P. P., Hong, Y. K., Kurdistani, S. K., Nakamura, M., Lu, K. P. and Lee, S. W. (2004) Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint. J. Biol. Chem. 279, 38597-38602
89. Mukhopadhyay, N. K., Cinar, B., Mukhopadhyay, L., Lutchman, M., Ferdinand, A. S., Kim, J., Chung, L. W., Adam, R. M., Ray, S. K., Leiter, A. B. et al. (2007) The zinc finger protein Ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol. Endocrinol. 21, 2056-2070
90. Chow, J. Y., Quach, K. T., Cabrera, B. L., Cabral, J. A., Beck, S. E. and Carethers, J. M. (2007) Ras/ERK modulates TGFβ-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28, 2321-2327
91. Lin, H. K., Hu, Y. C., Lee, D. K. and Chang, C. S. (2004) Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol. Endocrinol. 18, 2409-2423
92. Mulholland, D. J., Dedhar, S., Wu, H. and Nelson, C. C. (2006) PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 25, 329-337
93. Mulholland, D. J., Jiao, J. and Wu, H. (2008) Hormone refractory prostate cancer: Lessons learned from the PTEN prostate cancer model. Adv. Exp. Med. Biol. 617, 87-95
94. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J. et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113
95. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S. et al. (2007) A transforming mutation in the pleckstrin homology domain of Akt1 in cancer. Nature 448, U439-U431
96. E17K in human solid tumours. Oncogene 27, 5648-5650
97. Karakas, B., Bachman, K. E. and Park, B. H. (2006) Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94, 455-459
98. Leslie, N. R. and Downes, C. P. (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382, 1-11
99. Buck, M. B. and Knabbe, C. (2006) TGF-β signaling in breast cancer. Ann. N.Y. Acad. Sci. 1089, 119-126
100. Xu, Y. and Pasche, B. (2007) TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 16 (R1), R14-R20
101. Levy, L. and Hill, C. S. (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58
102. Jordan, A. and Reichard, P. (1998) Ribonucleotide reductases. Annu. Rev. Biochem. 67, 71-98
103. Buss, J. L., Torti, F. M. and Torti, S. V. (2003) The role of iron chelation in cancer therapy. Curr. Med. Chem. 10, 1021-1034
104. Kalinowski, D. S. and Richardson, D. R. (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 547-583
105. Richardson, D. R., Kalinowski, D. S., Lau, S., Jansson, P. J. and Lovejoy, D. B. (2008) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys., doi:10.1016/j.bbagen.2008.04.003
106. Cavill, I., Aurbach, M., Bailie, G. R., Barrett-Lee, P., Beguin, Y., Kaltwasser, P., Littlewood, T., Macdougall, I. C. and Wilson, K. (2006) Iron and anaemia of chronic disease: a review and strategic recommendations. Curr. Med. Res. Opin. 22, 731-737
107. Yuan, J., Lovejoy, D. B. and Richardson, D. R. (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450-1458
108. Whitnall, M., Howard, J., Ponka, P. and Richardson, D. R. (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 103, 14901-14906
109. Kalinowski, D. S., Yu, Y., Sharpe, P. C., Islam, M., Liao, Y. T., Lovejoy, D. B., Kumar, N., Bernhardt, P. V. and Richardson, D. R. (2007) Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 50, 3716-3729
110. Richardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M. and Bernhardt, P. V. (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 49, 6510-6521
111. Fu, D. and Richardson, D. R. (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110, 752-761
112. Nurtjahja-Tjendraputra, E., Fu, D., Phang, J. M. and Richardson, D. R. (2007) Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 109, 4045-4054
113. Dong, Z., Arnold, R. J., Yang, Y., Park, M. H., Hrncirova, P., Mechref, Y., Novotny, M. V. and Zhang, J. T. (2005) Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol. Cell. Proteomics 4, 993-1001
114. Hentze, M. W., Muckenthaler, M. U. and Andrews, N. C. (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117, 285-297
115. Zhang, P., Tchou-Wong, K. M. and Costa, M. (2007) Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Res. 67, 9125-9133
116. Baron, V., Adamson, E. D., Calogero, A., Ragona, G. and Mercola, D. (2006) The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13, 115-124
117. Bandyopadhyay, S., Pai, S. K., Hirota, S., Hosobe, S., Takano, Y., Saito, K., Piquemal, D., Commes, T., Watabe, M., Gross, S. C. et al. (2004) Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 23, 5675-5681
118. 2 in prostate cancer. Cancer Lett. 240, 9-16
119. 2 family. Prog. Lipid Res. 45, 487-510
120. Faas, F. H., Dang, A. Q., Pollard, M., Hong, X. M., Fan, K., Luckert, P. H. and Schutz, M. (1996) Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J. Urol. 156, 243-248
121. Paweletz, C. P., Ornstein, D. K., Roth, M. J., Bichsel, V. E., Gillespie, J. W., Calvert, V. S., Vocke, C. D., Hewitt, S. M., Duray, P. H., Herring, J. et al. (2000) Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 60, 6293-6297
122. Chetcuti, A., Margan, S. H., Russell, P., Mann, S., Millar, D. S., Clark, S. J., Rogers, J., Handelsman, D. J. and Dong, Q. (2001) Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 61, 6331-6334
123. Peppelenbosch, M. P., Tertoolen, L. G., Hage, W. J. and de Laat, S. W. (1993) Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 74, 565-575
124. Hughes-Fulford, M., Chen, Y. and Tjandrawinata, R. R. (2001) Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22, 701-707
125. Wang, Y., Corr, J. G., Thaler, H. T., Tao, Y., Fair, W. R. and Heston, W. D. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 87, 1456-1462
126. Nie, D., Che, M., Grignon, D., Tang, K. and Honn, K. V. (2001) Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 20, 195-206
127. Nie, D., Hillman, G. G., Geddes, T., Tang, K., Pierson, C., Grignon, D. J. and Honn, K. V. (1998) Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res. 58, 4047-4051
128. Pidgeon, G. P., Kandouz, M., Meram, A. and Honn, K. V. (2002) Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 62, 2721-2727
129. Porkka, K. P. and Visakorpi, T. (2004) Molecular mechanisms of prostate cancer. Eur. Urol. 45, 683-691